These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 29307477)

  • 1. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E.
    Liu Y; Liu X; Chen W; Yu Y; Meng J; Wang J
    Front Immunol; 2024; 15():1469919. PubMed ID: 39315101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
    Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
    Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the protective immune response against botulism.
    Przedpelski A; Tepp WH; Kroken AR; Fu Z; Kim JJ; Johnson EA; Barbieri JT
    Infect Immun; 2013 Jul; 81(7):2638-44. PubMed ID: 23670557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
    Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
    Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines against botulism.
    Karalewitz AP; Barbieri JT
    Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
    Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
    J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.
    Ruwona TB; Xu H; Li J; Diaz-Arévalo D; Kumar A; Zeng M; Cui Z
    Hum Vaccin Immunother; 2016 May; 12(5):1188-92. PubMed ID: 26837242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.
    Webb RP; Smith TJ; Wright P; Brown J; Smith LA
    Vaccine; 2009 Jul; 27(33):4490-7. PubMed ID: 19450643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant holotoxoid vaccine against botulism.
    Pier CL; Tepp WH; Bradshaw M; Johnson EA; Barbieri JT; Baldwin MR
    Infect Immun; 2008 Jan; 76(1):437-42. PubMed ID: 17967862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E.
    Li Z; Lu J; Tan X; Wang R; Xu Q; Yu Y; Yang Z
    Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202162
    [No Abstract]   [Full Text] [Related]  

  • 17. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
    Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
    Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
    Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
    Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.